Resident, Department of Breast Surgery
Breast Cancer Institute
Fudan University Shanghai Cancer Center
Studies suggest a survival benefit in breast cancer patients with pathological clinical response compared with patients with progressive disease following neoadjuvant chemotherapy, especially in triple negative breast cancer, which is associated with poorer prognosis. This result underscores the importance of defining the underlying biological characteristic of triple negative breast cancer. Recently, massively parallel DNA sequencing technologies have provided an unprecedented ability to screen entire genomes for genetic differences associated with tumor responses to neoadjuvant chemotherapy. Whole genome sequencing of breast cancer samples resistant to neoadjuvant chemotherapy consisting of paclitaxel and carboplatin in triple negative patients has not yet been reported. To identify the key molecules and signaling pathways that drive chemoresistance in triple negative patients, Dr. Liu and her colleagues have presented their initial analyses of whole genome and transcriptome sequencing data from pretreatment triple negative tumor biopsies accrued from patients in their clinical study of neoadjuvant paclitaxel and carboplatin chemotherapy. Dr. Liu plans to compare the results between different histopathological response groups (good- and bad-response) in which ten samples were defined to exhibit pathological complete response and the other ten exhibited PD in response to the progressive disease neoadjuvant chemotherapy. The collection of genomic alterations in these tumors, particularly those that may inform tumor chemoresistance, will be cataloged. Dr. Liu subsequently plans to examine interactions between biomarker changes (such as Ki67), histological categories, and mutation status in selected recurrently mutated genes in at least 250 cases overall. These data may identify a set of key molecular pathways selectively up-regulated or downregulated in chemoresistant cancer cells, which are appropriate targets for the development of future target therapies against breast cancer to overcome chemoresistance.
Dr. Zhe-Bin Liu obtained her doctorate from the Department of Breast Surgery of Fudan University Shanghai Cancer Center, which is one of the top medical institutions in China. During this period, she has conducted a number of clinical and translational research projects on metastatic breast cancer, the results of which have been published in Oncogene and the Journal of Biological Chemistry, among others. Dr. Liu was the first to report that the mannose-mediated EGFR pathway had a critical function in the mechanism of PA-MSHA. As a staff member of the Fudan Breast Cancer Institute, Dr. Liu has also been involved in several research projects. During the past few years, Dr. Liu has published five papers as the first author and at least 15 papers as the key author. In addition, she has grants from both the National Nature Science Foundation of China and Nature Science Foundation of Shanghai, which are the most recognized grants in China.
Dr. Liu’s past experience with the leading institutions of medical science in China has enabled her to build a strong foundation in clinical medicine and basic research.